Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, Hangzhou, 310009, Zhejiang, China.
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):765-783. doi: 10.1007/s00259-022-05999-z. Epub 2022 Nov 14.
Alzheimer's disease (AD) is the most common dementia worldwide. The exact etiology of AD is unclear as yet, and no effective treatments are currently available, making AD a tremendous burden posed on the whole society. As AD is a multifaceted and heterogeneous disease, and most biomarkers are dynamic in the course of AD, a range of biomarkers should be established to evaluate the severity and prognosis. Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease. In this review, we discuss the application of PET in the course of AD and summarized radiolabeled compounds with favorable imaging characteristics.
阿尔茨海默病（AD）是全球最常见的痴呆症。AD 的确切病因尚不清楚，目前也没有有效的治疗方法，这使得 AD 给整个社会带来了巨大的负担。由于 AD 是一种多方面和异质的疾病，并且大多数生物标志物在 AD 的病程中是动态变化的，因此应该建立一系列生物标志物来评估疾病的严重程度和预后。正电子发射断层扫描（PET）通过使用涉及各种病理生理过程的放射性标记试剂，为从多个角度可视化 AD 提供了极好的机会；PET 成像技术有助于全面探索 AD 的发病机制，并在每个 AD 阶段找到最合适的生物标志物，从而更好地评估疾病。在这篇综述中，我们讨论了 PET 在 AD 病程中的应用，并总结了具有良好成像特性的放射性标记化合物。
Zotero 插件
